| Title |
Intractable and highly active relapsing multiple sclerosis – role of alemtuzumab
|
|---|---|
| Published in |
Neuropsychiatric Disease and Treatment, September 2015
|
| DOI | 10.2147/ndt.s90473 |
| Pubmed ID | |
| Authors |
Divyanshu Dubey, Christopher A Cano, Olaf Stuve |
| Abstract |
Alemtuzumab is a humanized recombinant monoclonal antibody that was recently approved by the US Food and Drug Administration and the European Medicines Agency for the management of relapsing forms of multiple sclerosis (MS). It has been utilized for the management of chronic lymphocytic leukemia, bone marrow and renal transplantation, or graft versus host disease. Because of its immunomodulatory properties, it was brought into clinical development in MS. One Phase II (CAMMS223) and two Phase III clinical trials (CARE-MSI and -II) have evaluated the safety and efficacy of alemtuzumab in patients with relapsing-remitting MS. Even though its efficacy profile and long-lasting effect have attracted much interest among physicians and patients, it has significant potential adverse effects that may limit its use to patients with active disease. Here, we review the history of drug development of alemtuzumab. Furthermore, we outline the postulated mechanisms of action, clinical evidence, and safety of alemtuzumab for its use as a disease-modifying agent in active and highly active MS. |
X Demographics
The data shown below were collected from the profiles of 4 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 4 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 50% |
| Practitioners (doctors, other healthcare professionals) | 2 | 50% |
Mendeley readers
The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 91 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 20 | 22% |
| Student > Master | 15 | 16% |
| Other | 11 | 12% |
| Student > Ph. D. Student | 9 | 10% |
| Researcher | 8 | 9% |
| Other | 8 | 9% |
| Unknown | 20 | 22% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 25 | 27% |
| Biochemistry, Genetics and Molecular Biology | 9 | 10% |
| Neuroscience | 7 | 8% |
| Agricultural and Biological Sciences | 5 | 5% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 5% |
| Other | 16 | 18% |
| Unknown | 24 | 26% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 02 October 2015.
All research outputs
#14,727,269
of 25,576,275 outputs
Outputs from Neuropsychiatric Disease and Treatment
#1,305
of 3,141 outputs
Outputs of similar age
#128,129
of 277,197 outputs
Outputs of similar age from Neuropsychiatric Disease and Treatment
#42
of 95 outputs
Altmetric has tracked 25,576,275 research outputs across all sources so far. This one is in the 41st percentile – i.e., 41% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,141 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.6. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 277,197 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 95 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 53% of its contemporaries.